Literature DB >> 32282311

Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform.

İskender İnce1, Zümrüt Biber Müftüler1, E İlker Medine1, Özge Kozguş Güldü1, Gökhan Takan1, Ayşegül Ergönül2, Yasemin Parlak3, Yeliz Yıldırım4, Burcu Çakar5, Elvan Sayit Bilgin3, Ömer Aras6, Erdem Göker5, Perihan Ünak1.   

Abstract

BACKGROUND: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues.
OBJECTIVE: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy.
METHODS: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6-7- week-old nude mice utilized with bioluminescence imaging.
RESULTS: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively.
CONCLUSION: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  MRI; SPECT; Thymoquinone; iodine-131; lung cancer; magnetic nanoparticles; theranostics; thymoquinone glucuronide

Mesh:

Substances:

Year:  2021        PMID: 32282311      PMCID: PMC8500856          DOI: 10.2174/2211556009666200413085800

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  31 in total

Review 1.  Review on molecular and therapeutic potential of thymoquinone in cancer.

Authors:  Sanjeev Banerjee; Subhash Padhye; Asfar Azmi; Zhiwei Wang; Philip A Philip; Omer Kucuk; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

Review 2.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  99mTc-bisphosphonate-coated magnetic nanoparticles as potential theranostic nanoagent.

Authors:  Marija Mirković; Magdalena Radović; Dragana Stanković; Zorana Milanović; Drina Janković; Milovan Matović; Marija Jeremić; Bratislav Antić; Sanja Vranješ-Đurić
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2019-04-13       Impact factor: 7.328

4.  Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection.

Authors:  M N Nagi; M A Mansour
Journal:  Pharmacol Res       Date:  2000-03       Impact factor: 7.658

Review 5.  Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics.

Authors:  Kai Li; Hossein Nejadnik; Heike E Daldrup-Link
Journal:  Drug Discov Today       Date:  2017-04-26       Impact factor: 7.851

6.  Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma.

Authors:  Seiji Matsumoto; Fumihiro Tanaka; Kiyoshi Sato; Shinya Kimura; Taira Maekawa; Seiki Hasegawa; Hiromi Wada
Journal:  Lung Cancer       Date:  2009-01-28       Impact factor: 5.705

Review 7.  Clinical applications of magnetic drug targeting.

Authors:  A S Lübbe; C Alexiou; C Bergemann
Journal:  J Surg Res       Date:  2001-02       Impact factor: 2.192

8.  Investigation of therapeutic efficiency of bleomycin and bleomycin-glucuronide labeled with (131)I on the cancer cell lines.

Authors:  Melis Ediz; Uğur Avcıbaşı; Perihan Unak; Fazilet Zümrüt Biber Müftüler; Emin İlker Medine; Ayfer Yurt Kılçar; Hasan Demiroğlu; Fikriye Gül Gümüşer; Serhan Sakarya
Journal:  Cancer Biother Radiopharm       Date:  2013-01-25       Impact factor: 3.099

9.  Quantification of 89 Zr-Iron oxide nanoparticle biodistribution using PET-MR and ultrashort TE sequences.

Authors:  Caroline D Jordan; Misung Han; Sravani Kondapavulur; Denis Beckford Vera; Kiel D Neumann; Teri Moore; Carol Stillson; Roland Krug; Spencer Behr; Youngho Seo; Henry F VanBrocklin; Peder E Z Larson; Mark Wilson; Alastair J Martin; Steven W Hetts
Journal:  J Magn Reson Imaging       Date:  2018-05-14       Impact factor: 4.813

10.  Inflammatory bowel disease: MR- and SPECT/CT-based macrophage imaging for monitoring and evaluating disease activity in experimental mouse model--pilot study.

Authors:  Yingwei Wu; Karen Briley-Saebo; Jingyuan Xie; Ruihua Zhang; Zhongqiu Wang; Cijiang He; Cheuk Ying Tang; Xiaofeng Tao
Journal:  Radiology       Date:  2014-01-15       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.